Top Page
Revive Therapeutics
(RVV)
Revive Therapeutics (RVV) vs. S&P 500 (SPY)
Revive Therapeutics Business Overview & Revenue Model
Revive Therapeutics Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -164.00 | -328.00 | -434.00 | -578.00 | -775.00 | -28.27K | EBIT |
| -2.09M | -3.29M | -5.41M | -17.72M | -18.50M | -4.84M | EBITDA |
| -5.29M | -5.60M | -5.52M | -17.74M | -18.57M | -5.26M | Net Income Common Stockholders |
| -5.29M | -5.62M | -6.32M | -17.83M | -20.20M | -4.27M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 55.41K | 823.07K | 2.09M | 3.92M | 16.60M | 1.48M | Total Assets |
| 9.72M | 10.64M | 14.25M | 17.07M | 29.81M | 8.26M | Total Debt |
| 0.00 | 25.22K | 219.69K | 327.73K | 415.84K | 465.85K | Net Debt |
| -55.41K | -797.85K | -1.87M | -3.59M | -16.18M | -915.63K | Total Liabilities |
| 3.32M | 3.40M | 3.60M | 4.46M | 999.68K | 831.55K | Stockholders Equity |
| 6.39M | 7.23M | 10.65M | 12.60M | 28.81M | 7.43M |
| Cash Flow | Free Cash Flow | ||||
| -2.60M | -3.29M | -6.03M | -13.06M | -11.31M | -2.52M | Operating Cash Flow |
| -2.60M | -3.29M | -6.03M | -13.06M | -8.31M | -2.52M | Investing Cash Flow |
| -30.00K | 0.00 | 0.00 | 0.00 | -2.72M | 142.24K | Financing Cash Flow |
| 1.98M | 1.98M | 4.20M | 376.35K | 26.24M | 3.28M |
Revive Therapeutics Technical Analysis
Revive Therapeutics Peers Comparison
Revive Therapeutics Corporate Events
Revive Therapeutics Ltd. has announced a Shares for Debt Transaction to settle $150,000 in payables by issuing up to 6,000,000 common shares at $0.025 per share. This strategy aims to conserve cash for ongoing operations, with the transaction subject to customary closing conditions and a hold period for the shares. This move reflects Revive’s strategic financial management to support its operational needs and maintain its focus on therapeutic development.
Spark’s Take on TSE:RVV Stock
According to Spark, TipRanks’ AI Analyst, TSE:RVV is a Neutral.
The overall stock score for Revive Therapeutics is primarily influenced by significant financial challenges, such as no revenue and ongoing losses. Despite this, the company demonstrates short-term bullish technical indicators and has made strategic moves to expand its pipeline through recent acquisitions and collaborations. However, the negative P/E ratio and lack of profitability remain concerns.
To see Spark’s full report on TSE:RVV stock, click here.
Revive Therapeutics announced a collaboration with a U.S. University Cancer Institute to investigate Bucillamine’s potential in treating advanced solid tumors. This study, supported by NIH funding, aims to enhance anti-tumor effects by using Bucillamine to adjust the tumor microenvironment, potentially improving treatment outcomes for cancer patients.
Spark’s Take on TSE:RVV Stock
According to Spark, TipRanks’ AI Analyst, TSE:RVV is a Neutral.
Revive Therapeutics’ overall score reflects significant financial challenges, with no revenue and ongoing losses. However, technical indicators show short-term bullish momentum, and recent corporate events suggest potential strategic improvements. Valuation remains a concern due to negative earnings, but the company’s efforts to expand its pipeline could offer future growth opportunities.
To see Spark’s full report on TSE:RVV stock, click here.
Revive Therapeutics has acquired the molecular hydrogen program from DiagnaMed Holdings, expanding its pipeline to include potential treatments for neurological and mental health disorders such as ALS, Dementia, and Depression. This acquisition, which includes a provisional patent application and an Orphan Drug Designation by the FDA for ALS, positions Revive to accelerate its development programs, offering hope to patients with limited treatment options.
Revive Therapeutics announced the results of its annual shareholder meeting, where key decisions included the election of board members and the appointment of Horizon Assurance LLP as the company’s auditor. The board also decided against amending the company’s articles to consolidate common shares, reflecting shareholder feedback. This meeting underscores Revive’s commitment to aligning with shareholder interests and maintaining strategic focus on its therapeutic development programs.
Revive Therapeutics has announced a non-binding letter of intent to acquire DiagnaMed’s molecular hydrogen program, which includes intellectual property for potential treatments of neurological and mental health disorders. This acquisition, expected to close by March 31, 2025, aims to advance the clinical development of molecular hydrogen, particularly for ALS, a disease with limited treatment options. The FDA’s orphan drug designation for molecular hydrogen in ALS provides hope for affected patients, and Revive plans to collaborate with researchers and advocacy groups to expedite its development. Additionally, Revive has secured a $65,000 loan to assist with its current working capital needs.